Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Arcus Biosciences Inc before investing.

In this article, we go over a few key elements for understanding Arcus Biosciences Inc’s stock price such as:

• Arcus Biosciences Inc’s current stock price and volume
• Why Arcus Biosciences Inc’s stock price changed recently
• Upgrades and downgrades for RCUS from analysts
• RCUS’s stock price momentum as measured by its relative strength

About Arcus Biosciences Inc (RCUS)

Before we jump into Arcus Biosciences Inc’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately five clinical programs that are focused on targets, including TIGIT, PD-1, HIF-2a, adenosine A2a and A2b receptors and CD73. It is evaluating three antibodies and three small molecules across 13 different clinical studies, including four Phase III studies. It is developing two investigational anti-TIGIT monoclonal antibodies, which include domvanalimab (Fc-silent) and AB308 (Fc-enabled). HIF-2a is a master transcriptional regulator of multiple genes involved in tumor progression. The Company's investigational products also include etrumadenant and quemliclustat.

Want to learn more about Arcus Biosciences Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Arcus Biosciences Inc.

Arcus Biosciences Inc’s Stock Price as of Market Close

As of November 14, 2023, 4:00 PM, CST, Arcus Biosciences Inc’s stock price was $14.39.

Arcus Biosciences Inc is up 7.15% from its previous closing price of $13.43.

During the last market session, Arcus Biosciences Inc’s stock traded between $12.95 and $13.58. Currently, there are 74.60 million shares of Arcus Biosciences Inc stock available for purchase.

Unfortunately, Arcus Biosciences Inc’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

Arcus Biosciences Inc Stock Price History

Arcus Biosciences Inc’s (RCUS) price is currently down 8.4% so far this month.

During the month of November, Arcus Biosciences Inc’s stock price has reached a high of $16.95 and a low of $12.95.

Over the last year, Arcus Biosciences Inc has hit prices as high as $36.13 and as low as $12.95. Year to date, Arcus Biosciences Inc’s stock is down 64.44%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Arcus Biosciences Inc Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of November 13, 2023, there was 1 analyst who downgraded Arcus Biosciences Inc’s stock and 8 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Arcus Biosciences Inc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Arcus Biosciences Inc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Arcus Biosciences Inc’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Arcus Biosciences Inc (RCUS) by visiting AAII Stock Evaluator.

Relative Price Strength of Arcus Biosciences Inc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 13, 2023, Arcus Biosciences Inc has a weighted four-quarter relative price strength of -19.81%, which translates to a Momentum Score of 20 and is considered to be Very Weak.

Want to learn more about how Arcus Biosciences Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Arcus Biosciences Inc Stock Price: Bottom Line

As of November 14, 2023, Arcus Biosciences Inc’s stock price is $14.39, which is up 7.15% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Arcus Biosciences Inc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.